Navigation Links
Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
Date:11/4/2010

n to focus its resources on the continued development of picoplatin, the Company's assessment of the commercial and therapeutic potential of picoplatin, the Company's plan to explore strategic alternatives to support the continued development of picoplatin, and the Company's goal of optimizing and realizing shareholder value from picoplatin. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including the Company's anticipated future operating losses, need for future capital and ability to obtain future funding on favorable terms or at all; the risk that strategic relationships may not be established on a timely basis, on terms that are ultimately favorable to the Company, or at all; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's ability to retain key personnel; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of FDA and other required regulatory approvals, if at all; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company u
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Corporation has announced the release of its next-generation slide scanners, ... of the original series, the NanoZoomer 2.0 converts a 20 ... a 1.9-gigapixel color image in as little as 1 minute ... on a computer monitor, shared across computer networks, used for ...
... , CRANBURY, N.J., Oct. 7 Cornerstone Pharmaceuticals, Inc., ... research scientist Robert A. Weinberg, Ph.D., a founding member ... Professor of Biology at MIT, has joined the company,s ... discoveries of the first human oncogene (the ras ...
Cached Medicine Technology:New 'Virtual Microscope' System from Hamamatsu Offers Faster Acquisition of High-Resolution Slide Scans 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 2Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board 3
(Date:4/24/2014)... the first flu pandemic in the 21st century. The ... than 50 people in the country. Since 2011 the ... seasons). , Infections with influenza pH1N1 virus vary ... has recommended Tamiflu for treatment of patients with severe ... that it targets viral proteins which mutate quickly and ...
(Date:4/23/2014)... donors was safe and effective in treating patients ... difficile , according to a new pilot study ... available online. Known as fecal microbiota transplantation, the ... colonoscope or a nasogastric tube. The findings suggest ... readily available to patients. , A growing concern, ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... University researchers have identified an important enzyme pathway that ... too few chromosomes, a condition that has been directly ... associate professor of biochemistry, found that near the end ... enzyme that ensures any breaks in DNA are fully ... genome to daughter cells. This process helps safeguard against ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... , , LA JOLLA, Calif., July ... of TLC(R) Dark Mocha Almond Chewy Granola Bar as the latest ... This new granola bar combines crunchy roasted almonds with rich dark chocolate ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090331/LA91619LOGO ) , , ...
... , NEWARK, Calif., July 21 Novasys Medical, ... urinary incontinence, announced today that it has received $18.95 million in ... financing. The Company received the first tranche of the Series D ... investors ThreeArch Partners and Skyline Ventures. All three participated in the ...
... , , , ... 21 In an unprecedented and historic show of unity, advocates for ... G-8 countries with reneging on their commitments to health by chronically underfunding ... and health systems strengthening across the globe. , ...
... ... design with antibacterial effectiveness. , ... Portland, OR (Vocus) July 21, 2009 -- HemCon Medical Technologies, Inc. ... a next generation, z-folded hemostatic chitosan dressing, designed for battlefield and acute care use ...
... , LAS VEGAS, July 21 ... its subsidiary, Disability Access Corporation (Pink Sheets: DBYC), its wholly ... $245,000 contract with Tuolumne Joint Powers Authority to provide inspection ... exceed $120,000) with the Office of the Independent Monitor for ...
... , , MADISON, N.J., July ... world,s leading provider of diagnostic testing, information and services, announced that ... operations rose to $188 million, or $1.00 per diluted share, from ... of 2008. These results include a previously disclosed benefit associated with ...
Cached Medicine News:Health News:Kashi Company Introduces TLC(R) Dark Mocha Almond Chewy Bar 2Health News:Novasys Medical Receives $18.95 Million in Second Tranche of Series D Financing 2Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 2Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 3Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 4Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 5Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 6Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 7Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 8Health News:Next-Generation Hemostatic Dressing Available for Military Emergencies 2Health News:Next-Generation Hemostatic Dressing Available for Military Emergencies 3Health News:PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009 2Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 2Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 3Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 4Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 5Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 6Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 7Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 8Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 9Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 10Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 11Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 12Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 13Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 14
Plastic micro-hematocrit capillary tubes from Globe Scientific Inc. are designed for use in 75 mm (3 inches) hematocrit centrifuges and come with many features....
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
... Vivid 3 system is designed to address ... performance, and offer an even wider range ... the OR. From color flow imaging with ... new Vivid 3 offers a wealth of ...
... Volcano's new VH IVUS technology ... allow simplified interpretation of ultrasound images ... composition of each patient's atherosclerotic plaques. ... plaque component types: fibrous, fibro-fatty, dense ...
Medicine Products: